Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:59 2024-04-26 am EDT			5-day change	1st Jan Change
8.78 ^SEK	-1.79%		-2.23%	-4.98%

Feb. 23	Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
Feb. 21	Initiator Pharma Issues New Shares for Debt Conversion	MT

Initiator Pharma - Q4 2023 – Breathing optimism

February 23, 2024 at 05:20 am EST

Redeye provides a research update following the Q4 report published by Initiator Pharma earlier today. The company operated at a lower OPEX than we anticipated, while managing to achieve a positive new cash flow, showing promise for the financial runway ahead. Following the encouraging phase IIb topline results announced by the company during the quarter, full priority for 2024 will be to find a licensing partner for pudafensine. We reiterate our fair value range with a base case valuation of SEK24 as we continue to have a positive outlook on the case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Latest news about Initiator Pharma A/S

Initiator Pharma A/S Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Initiator Pharma Issues New Shares for Debt Conversion	Feb. 21	MT
Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts	Jan. 08	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 10	CI
Initiator Pharma A/S Announces Positive Results from Phase IIb Clinical Trial with Pudafensine	23-10-06	CI
Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction	23-09-19	CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-25	CI
Initiator Pharma Wins EU Patent for Erectile Dysfunction, Depression Drug Candidate	23-08-09	MT
Initiator Pharma A/S Obtains IP 2018 Patent in Europe for Treatment of Erectile Dysfunction and Depression	23-08-09	CI
Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial	23-07-18	CI
Initiator Pharma A/S (OM:INIT) commences an Equity Buyback Plan for 10% of its issued share capital, under the authorization approved on May 26, 2023.	23-07-05	CI
Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine	23-06-29	CI
Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction	23-06-05	CI
Initiator Pharma A/S's Equity Buyback announced on July 25, 2022 has expired.	23-05-25	CI
Initiator Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	23-05-02	CI
Initiator Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23-05-02	CI
Initiator Pharma A/S Completes Dosing in Phase 2a Trial with IP2018	23-03-06	CI
Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations	22-12-20	CI
Tranche Update on Initiator Pharma A/S (OM:INIT)'s Equity Buyback Plan announced on July 25, 2022.	22-11-04	CI
Initiator Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-04	CI
Initiator Pharma A/S Provides an Update on Its Clinical Programs	22-11-04	CI
Certain Ordinary Shares of Initiator Pharma A/S are subject to a Lock-Up Agreement Ending on 3-OCT-2022.	22-10-02	CI
Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study	22-09-21	CI
Initiator Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI

Chart Initiator Pharma A/S

Duration

Period

More charts

Company Profile

Initiator Pharma A/S is a Denmark-based company engaged in the biotechnology sector. The Company focuses on developing drugs for treatment of erectile dysfunction.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INITIATOR PHARMA A/S	-4.98%	42.37M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research

Initiator Pharma A/S

Equities

INIT

DK0060775872

Biotechnology & Medical Research

Initiator Pharma - Q4 2023 – Breathing optimism

Latest news about Initiator Pharma A/S

Chart Initiator Pharma A/S

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research